GLP1R Genetics Points Toward Psoriatic Disease
A genetic study links higher GLP1R expression with lower psoriasis and psoriatic arthritis risk. It raises a research question; it does not establish that a GLP-1 drug treats either disease.
A signal in susceptibility, not a treatment result
A 2026 British Journal of Dermatology study used genetic variants associated with GLP1R expression in whole blood to investigate psoriatic disease risk. Higher genetically proxied expression was associated with lower risk of psoriasis (odds ratio 0.72) and psoriatic arthritis (0.48) in European-ancestry datasets. The association persisted after adjustment for genetic proxies of several metabolic traits. These are population-level genetic estimates, not responses measured after a GLP-1 drug. [1]
The pattern is disease-specific
The same analysis found no evidence of a protective association for acne, eczema, asthma or several other conditions. It found associations in the opposite direction for Crohn disease and rheumatoid arthritis. The authors caution that those genetic results do not show that prescribed GLP-1 receptor agonists worsen either disease. A pathway may matter differently across tissues and conditions; a single immune-disease claim would erase that distinction. [1]
What a development program would still need
The study examined lifelong genetic differences rather than a defined drug, dose or treatment period. Its co-localization analysis did not robustly establish a shared causal variant, and the outcome datasets were restricted to European ancestry. Mechanistic work and clinical studies must test whether changing GLP-1R activity can alter disease outcomes. A topical route adds a separate question: can an active reach the relevant skin tissue at a useful exposure? This paper does not answer it. [1]